SELLAS Life Sciences Group Gets FDA Orphan Drug Designation For Acute Myeloid Leukemia Treatment
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Group has received FDA Orphan Drug Designation for its Acute Myeloid Leukemia treatment. This designation provides certain benefits, including tax credits for clinical testing.
October 10, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences Group's Acute Myeloid Leukemia treatment has received FDA Orphan Drug Designation, which could provide financial benefits and expedite the drug's path to market.
The FDA Orphan Drug Designation is granted to drugs that treat rare diseases, providing benefits like tax credits for clinical testing. This could expedite the drug's path to market and provide financial benefits to SELLAS, potentially boosting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100